UPDATE: Needham & Company Upgrades Acadia Pharmaceuticals (ACAD) to Buy, $9 Price Target
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- Wall Street indexes slip as oil prices rise, retail results awaited
- Trump threatens to bomb Oman over Iran stance
- Why this Wall Street strategist says the "trade is long gold"
- U.S. EV market shows signs of bottoming out: Bernstein
- Micron rises as White House presses Apple to avoid Chinese memory chips
- Wall Street indexes slip as oil prices rise, retail results awaited
- Oil settles up over $2 as Iran war stalemate stokes supply concerns
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Micron rises as White House presses Apple to avoid Chinese memory chips
- Trump threatens to bomb Oman over Iran stance
Acadia Pharma (ACAD) Met Primary Endpoint in Pimavanserin Phase III
November 27, 2012 7:27 AM ESTAcadia Pharmaceuticals, Inc. (NASDAQ: ACAD) announced successful top-line results from its pivotal Phase III trial evaluating the efficacy, tolerability and safety of pimavanserin in patients with Parkinsons disease psychosis (PDP). Pimavanserin is ACADIAs proprietary, non-dopaminergic product candidate that selectively blocks serotonin 5-HT2A receptors. Pimavanserin met the primary endpoint in the Phase III trial by demonstrating highly significant antipsychotic efficacy as measured using the 9-item SAPS-PD scale (p=0.001). Pimavanserin also met the key secondary endpoint for motoric tolerability as measured using Parts II and III of the Unified Parkinsons Disease Rating Scale,... More
Acadia Pharma (ACAD) Halted Ahead of Pivotal Pimavanser Phase III Presentation
November 27, 2012 7:25 AM ESTAcadia Pharmaceuticals, Inc. (NASDAQ: ACAD) shares are halted Tuesday morning ahead of the company's conference call and webcast to present the top-line results from its pivotal Phase III trial with pimavanserin in patients with Parkinsons disease psychosis (PDP).
The... More
Acadia Pharmaceuticals (ACAD) Jumps Ahead of Data Presentation
November 26, 2012 5:47 PM ESTShares of Acadia Pharmaceuticals, Inc. (NASDAQ: ACAD) are up 6.5 percent after-hours Monday after the company announced that it will host a conference call and webcast at 8:00 a.m. Eastern Time on Tuesday, November 27, 2012 to present the top-line results from its pivotal Phase III trial with... More
